Communicable Diseases and Interventional Vaccines, Annotated Bibliography Example

The following annotated bibliography will address the relationship between communicable diseases and interventional vaccines and how this demonstrates a need to consider different options in supporting an environment where vaccinations are likely to have a positive impact on patients.

Takahashi, S., Metcalf, C. J. E., Ferrari, M. J., Moss, W. J., Truelove, S. A., Tatem, A. J., … & Lessler, J. (2015). Reduced vaccination and the risk of measles and other childhood infections post-Ebola. Science, 347(6227), 1240-1242.

This article addresses the Ebola virus and how it impacts the risk of childhood infectious diseases such as Measles. Therefore, it is important to consider children who are at risk of Measles due to lack of vaccination and the emergence of the Ebola virus. This reflects a greater need to expand vaccination efforts to ensure that children receive these vaccinations in a timely manner to prevent further risk.

Gidengil, C., Lieu, T. A., Payne, K., Rusinak, D., Messonnier, M., & Prosser, L. A. (2012). Parental and societal values for the risks and benefits of childhood combination vaccines. Vaccine, 30(23), 3445-3452.

This article addresses the importance of new combination vaccines to reduce the number of injections required, but also represents a higher level of risk and potential adverse events for some patients. This reflects a need to evaluate if the benefits of combination vaccines outweigh the risks and if this is effective in supporting a more cost-effective approach to vaccinations for children and adults. It is important to identify areas where combination vaccines might be useful and effective so that patients may not be required to undergo multiple injections to promote convenience and cost savings, while also considering the risks of this practice.

Desai, R., Cortese, M. M., Meltzer, M. I., Shankar, M., Tate, J. E., Yen, C., … & Parashar, U. D. (2013). Potential intussusception risk versus benefits of rotavirus vaccination in the United States. The Pediatric infectious disease journal, 32(1), 1-7.

This article addresses the significance of rotavirus vaccination and an increased risk of intussusception in some patients. This risk appears to be minimal, however, and reflects a need to further evaluate the conditions under which rotovirus cases would increase in the event that vaccinations were not administered to patients in a timely manner. Therefore, the benefits of these vaccinations outweigh the risks and reflect the importance of continuing to use this vaccination to prevent rotovirus.

Kiatpongsan, S., Campos, N. G., & Kim, J. J. (2012). Potential benefits of second-generation human papillomavirus vaccines. PloS one, 7(11), e48426.

This article addresses the importance of second-generation vaccines for human papillomavirus (HPV) have been critical in the development of new types of the virus that have emerged in recent years. This is an important tool in promoting a higher level of vaccination among patients with the use of current and second-generation types. However, the risk of infection of other types in conjunction with vaccine type must also be considered in order to further evaluate the overall risks and benefits of these vaccines.

Hampton, T. (2014). Largest-ever outbreak of Ebola virus disease thrusts experimental therapies, vaccines into spotlight. JAMA, 312(10), 987-989.

This article addresses the significance of the growth of the Ebola virus epidemic over the past several years and how this has created new inquiries regarding vaccination for the disease in order to prevent expansive outbreaks. With the continued interest in the disease on an international scale, research into vaccinations and treatment has been largely instrumental in advancing the objectives required to introduce and test new vaccination therapies, along with treatments that may limit the progress of the disease over time. This is essential in promoting greater interest in expanding resources to increase interest in vaccinations throughout the world.

Robinson, J. (2013). New vaccines–which ones should we choose?. The Canadian Journal of Infectious Diseases & Medical Microbiology, 24(4), 177.

This article addresses the importance of newly developed vaccines and the decisions that are required to ensure that these vaccines are utilized appropriately and in a timely manner to prevent new disease outbreaks. This is an important step in determining which vaccines carry risks and whether or not these risks outweigh the benefits of the vaccine itself. There is a critical need to evaluate these conditions and to determine how to best provide for specific populations who are at risk of infectious diseases and what is required to manage these risks as best as possible. This reflects the importance of supporting a vaccination research, testing, and integration environment that will have a lasting impact on the populations who will be served by these vaccines for the foreseeable future.

Demicheli, V., Rivetti, A., Debalini, M. G., & Di Pietrantonj, C. (2013). Vaccines for measles, mumps and rubella in children. Evidence?Based Child Health: A Cochrane Review Journal, 8(6), 2076-2238.

This article addresses the importance of vaccinations for measles-mumps-rubella (MMR) for patients up to 15 years of age. Based upon the studies that were evaluated, it was determined that the vaccine has a 95 percent effectiveness rate in preventing the measles, along with and 92 percent effectiveness rate in preventing secondary cases within a given household. This reflects the importance of the MMR vaccine and how it impacts children and teenagers in an effective manner.

Ogbuanu, I. U., Kutty, P. K., Hudson, J. M., Abedi, G. R., Goodell, S., Lawler, J., … & Gallagher, K. (2012). Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics, 130(6), e1567-e1574.

This article addresses the importance of receiving third doses of the measles-mumps-rubella vaccine, as this provides further protection against the risk of contracting mumps. In addition, those who are vaccinated for a third time are likely to have fewer side effects and are able to reduce their risk at a higher rate, particularly between the ages of 11 and 17, thereby noting that a third vaccination appears to be generally safe for patients.

Fox, A. T., Swan, K. E., Perkin, M., Toit, G., & Lack, G. (2014). The changing pattern of measles, mumps and rubella vaccine uptake in egg?allergic children.Clinical & Experimental Allergy, 44(7), 999-1002.

This article addresses the significance of children with egg allergies who take the measles-mumps-rubella vaccine, which is comprised of virus that is associated with the fibroblasts of a chick. The article notes that there is a greater risk associated with not having the vaccine than in obtaining it, as it appears to be safe in children who have existing egg allergies. This ensures that children are protected from these diseases as best as possible.

Zachariah, P., Posner, A., Stockwell, M. S., Dayan, P. S., Sonnett, F. M., Graham, P. L., & Saiman, L. (2014). Vaccination Rates for Measles, Mumps, Rubella, and Influenza Among Children Presenting to a Pediatric Emergency Department in New York City. Journal of the Pediatric Infectious Diseases Society, piu005.

This article addresses the role of surveillance in recognizing the vaccination status of pediatric patients who enter the emergency department, including measles-mumps-rubella. This process requires an examination of whether or not a vaccination has occurred has an impact on a patient’s risk of contracting one of these diseases. This article reflects a greater need to evaluate patients for their history of vaccinations in order to prevent further complications among children who face the risk of these diseases in the emergency department setting.

References

Demicheli, V., Rivetti, A., Debalini, M. G., & Di Pietrantonj, C. (2013). Vaccines for measles, mumps and rubella in children. Evidence?Based Child Health: A Cochrane Review Journal, 8(6), 2076-2238.

Desai, R., Cortese, M. M., Meltzer, M. I., Shankar, M., Tate, J. E., Yen, C., … & Parashar, U. D. (2013). Potential intussusception risk versus benefits of rotavirus vaccination in the United States. The Pediatric infectious disease journal, 32(1), 1-7.

Fox, A. T., Swan, K. E., Perkin, M., Toit, G., & Lack, G. (2014). The changing pattern of measles, mumps and rubella vaccine uptake in egg?allergic children.Clinical & Experimental Allergy, 44(7), 999-1002.

Gidengil, C., Lieu, T. A., Payne, K., Rusinak, D., Messonnier, M., & Prosser, L. A. (2012). Parental and societal values for the risks and benefits of childhood combination vaccines. Vaccine, 30(23), 3445-3452.

Hampton, T. (2014). Largest-ever outbreak of Ebola virus disease thrusts experimental therapies, vaccines into spotlight. JAMA, 312(10), 987-989.

Kiatpongsan, S., Campos, N. G., & Kim, J. J. (2012). Potential benefits of second-generation human papillomavirus vaccines. PloS one, 7(11), e48426.

Ogbuanu, I. U., Kutty, P. K., Hudson, J. M., Abedi, G. R., Goodell, S., Lawler, J., … & Gallagher, K. (2012). Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics, 130(6), e1567-e1574.

Robinson, J. (2013). New vaccines–which ones should we choose?. The Canadian Journal of  Infectious Diseases & Medical Microbiology, 24(4), 177.

Takahashi, S., Metcalf, C. J. E., Ferrari, M. J., Moss, W. J., Truelove, S. A., Tatem, A. J., … & Lessler, J. (2015). Reduced vaccination and the risk of measles and other childhood infections post-Ebola. Science, 347(6227), 1240-1242.

Zachariah, P., Posner, A., Stockwell, M. S., Dayan, P. S., Sonnett, F. M., Graham, P. L., & Saiman, L. (2014). Vaccination Rates for Measles, Mumps, Rubella, and Influenza Among Children Presenting to a Pediatric Emergency Department in New York City. Journal of the Pediatric Infectious Diseases Society, piu005.